PHIL Stock Overview
Philadelphia Pharmaceuticals Company develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Philadelphia Pharmaceuticals Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.أ1.38 |
| 52 Week High | د.أ1.49 |
| 52 Week Low | د.أ1.30 |
| Beta | -0.012 |
| 1 Month Change | -7.38% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | 2.99% |
| 5 Year Change | -17.86% |
| Change since IPO | 98.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHIL | JO Pharmaceuticals | JO Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | 2.3% |
| 1Y | 0% | -2.6% | -1.0% |
Return vs Industry: PHIL exceeded the JO Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: PHIL matched the JO Market which returned -1% over the past year.
Price Volatility
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JO Market | 6.1% |
| 10% least volatile stocks in JO Market | 1.7% |
Stable Share Price: PHIL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHIL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 133 | Ashraf Ahmad Hussein | www.philapharma.com |
Philadelphia Pharmaceuticals Company develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan. The company provides products for skin related disorders, including anti-lice and scabicides preparations, antiseptics and disinfectants, bleaching and hyperpigmentation disorders preparations, emollients and protectives, keratolytics/topical psoriasis treatment preparations, and skin healing agents, as well as agents for dermatitis; and topical acne preparation, anti-pruritic, anti-viral, plain antifungal and anti-infective, plain steroid, steroids with antifungal/anti-infective combination, and skin recoloring products. It also offers products for women health, such as vaginal antifungals, alkalinizing and cleansing agents, antimicrobials, germicidal fungicidal, antiseptics and hemostatic, and vaginal progesterone; and products in the areas of alimentary, gastrointestinal system, anti-inflammatory, analgesic, antipyretic, dental-oropharyngeal, hair care, local anesthetics, and respiratory system, as well as supplements and health care-OTC products.
Philadelphia Pharmaceuticals Company Fundamentals Summary
| PHIL fundamental statistics | |
|---|---|
| Market cap | د.أ10.35m |
| Earnings (TTM) | د.أ807.20k |
| Revenue (TTM) | د.أ8.40m |
12.8x
P/E Ratio1.2x
P/S RatioIs PHIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIL income statement (TTM) | |
|---|---|
| Revenue | د.أ8.40m |
| Cost of Revenue | د.أ4.40m |
| Gross Profit | د.أ4.00m |
| Other Expenses | د.أ3.20m |
| Earnings | د.أ807.20k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 47.64% |
| Net Profit Margin | 9.60% |
| Debt/Equity Ratio | 11.7% |
How did PHIL perform over the long term?
See historical performance and comparison